Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from DNA or a gene-modified virus may help the body build an
effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may
stimulate the immune system in different ways and stop tumor cells from growing. Applying
topical imiquimod to the cervix may be an effective treatment for cervical intraepithelial
neoplasia. Giving vaccine therapy together with imiquimod may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy and
to see how well it works when given with or without imiquimod in treating patients with grade
3 cervical intraepithelial neoplasia.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins